GlobeNewswire by notified

Philips announces exchange ratio for 2022 dividend

Share

May 17, 2023

Amsterdam, the Netherlands –
Royal Philips (NYSE: PHG; AEX: PHIA) today announced that the exchange ratio for the dividend for the year 2022 is 1 new common share for every 22.3906 existing common shares. This ratio was based on the volume weighted average price on Euronext Amsterdam of May 11, 12 and 15, 2023, of EUR 19.0020 and was calculated in a manner that the gross dividend in shares will be approximately equal to EUR 0.85. As a result, Philips will issue a total number of 39,334,938 new common shares.

Distribution of the dividend with delivery of new common shares and settlement of any fractions in cash, will take place from May 18, 2023. Upon distribution, the total issued share capital will amount to EUR 185,730,004, representing 928,650,020 common shares.

Before the end of the year, Philips expects to cancel a total of 15,134,054 shares. The shares to be cancelled include treasury shares already held and shares yet to be acquired in the course of 2023 through the settlement of forward contracts entered into as part of the EUR 1.5 billion share repurchase program for capital reduction purposes, as announced on July 26, 2021. More information is available via this link.

For further information, please contact:

Elco van Groningen
Philips Global Press Office
Tel.: +31 6 8103 9584
E-mail: elco.van.groningen@philips.com

Derya Guzel
Philips Investor Relations
Tel.: +31 20 59 77055
E-mail: derya.guzel@philips.com

About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2022 sales of EUR 17.8 billion and employs approximately 74,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Forward-looking statements
This release contains certain forward-looking statements with respect to the financial condition, results of operations and business of Philips and certain of the plans and objectives of Philips with respect to these items. Examples of forward-looking statements include statements made about the strategy, estimates of sales growth, future EBITA, future developments in Philips’ organic business and the completion of acquisitions and divestments. By their nature, these statements involve risk and uncertainty because they relate to future events and circumstances and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these statements.

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Første uge i tilbudsperioden i Jobindex A/S10.6.2023 12:00:37 CEST | pressemeddelelse

Danielsen 2 aps - der er hovedaktionær i Jobindex A/S - har den 2. juni 2023 fremsat et frivilligt ureguleret offentligt købstilbud om at købe aktier i Jobindex A/S til en pris på 1900 kr. pr. aktie i forbindelse med ansøgning om afnotering fra First North. På tilbudsperiodens tredje og fjerde dag har Danielsen 2 aps købt 1212 og 944 aktier á 1900 kr. pr. aktie. Den første uge har Danielsen 2 aps i alt købt 4645 aktier. Tilbudsperioden fortsætter indtil den 30. juni 2023. Det forventes at Jobindex A/S derefter vil blive afnoteret og slettet fra handel på Nasdaq First North i henhold til punkt 2.6(c)(i) i Supplement D i Nasdaqs regler. Yderligere oplysninger Direktør Kaare Danielsen, telefon 20735010, email kd@jobindex.dk Certified Adviser Jakob Tolstrup Kristensen, email jakob.tolstrup@cwicf.com Vedhæftet fil Aktiehandel tilbud 2023 juni 9

PRIX FITZGERALD 2023 LAUREATE ANNOUNCED AT HÔTEL BELLES RIVES10.6.2023 01:03:24 CEST | Press release

Quentin Tarantino Accepts 12th Annual Literary Award for Cinema Speculation CAP D’ANTIBES, France, June 09, 2023 (GLOBE NEWSWIRE) -- During an unforgettable ceremony held this evening Hôtel Belles Rives in Juan-les-Pins on the French Riviera, jury members of the 2023 Prix Fitzgerald, a French literary award created in 2011 by Marianne Estène-Chauvin, President of the Francis Scott Fitzgerald Academy and owner of Belles Rives Group, announced today this year’s laureate. The long-awaited first work of nonfiction from the author of the #1 New York Times bestselling Once Upon a Time in Hollywood, Quentin Tarantino accepted the prize for Cinema Speculation, published by HarperCollins in the United States and Weidenfeld & Nicolson in the United Kingdom on November 1, 2022 and French publishing house, Flammarion on March 22, 2023. Every year in June, the Hôtel Belles Rives hosts the Prix Fitzgerald, which honors a novel or short story that reflects the elegance, spirit, and art of living embo

FDA Advisory Committee Votes Unanimously to Confirm the Clinical Benefit of LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer’s Disease10.6.2023 00:45:00 CEST | Press release

Peripheral and Central Nervous System Drugs Advisory Committee votedbased on data from large global confirmatory Phase 3 Clarity AD clinical trial in patients living with early Alzheimer’s disease The PDUFA action date for traditional approval of LEQEMBI has been set for July 6, 2023, with designation of priority review LEQEMBI received accelerated approval from the FDA for the treatment of early Alzheimer’s disease on January 6, 2023 TOKYO and CAMBRIDGE, Mass., June 09, 2023 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the U.S. Food and Drug Administration’s (FDA) Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) voted unanimously that the data from Eisai’s Phase 3 Clarity AD clinical trial confirms the clinical benefit of LEQEMBI® (lecanemab-irmb) 100 mg/mL injection for intravenous

Travel Startup Yovivo Expands Core Team With New Staff Members9.6.2023 20:47:00 CEST | Press release

Extended stays booking site hires Karen Kochmann (Ex-Expedia) and Erik Beekman (Ex Savills) to keep up with its fast expansion ROTTERDAM, Netherlands, June 09, 2023 (GLOBE NEWSWIRE) -- Growing startup Yovivo.com today announced its latest team expansion with the addition of two key members from the travel and real estate industries. Karen Kochmann has been taken on by Yovivo in the position of Strategic Growth Manager. Formerly Expedia’s Account Manager for the Balearic Islands (where the Yovivo offices and team are located), Karen boasts over seven years of experience, a masters degree in Digital Marketing and E-commerce, and a Banking degree from Lauder Business School. “I plan to developing strategic partnerships which will help Yovivo grow and position itself as a leading brand for extended stays. With my experience in the field of tech and tourism I will be able to bring fresh ideas to both the development of the platform and the B2C and B2B approach planned. I'll also focus on cr

Nokia Corporation: Repurchase of own shares on 09.06.20239.6.2023 20:00:00 CEST | Press release

Nokia Corporation Stock Exchange Release 9 June 2023 at 21:00 EEST Nokia Corporation: Repurchase of own shares on 09.06.2023 Espoo, Finland – On 9 June 2023 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL323,9103.77CEUX33,5313.77AQEU1,0683.77TQEX14,9913.77Total373,5003.77 * Rounded to two decimals On 3 February 2022, Nokia announced that its Board of Directors is initiating a share buyback program under the authorization granted by Nokia’s Annual General Meeting on 8 April 2021 to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The second phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 5 April 2022 started on 2 January 2023 and e